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Abstract
Metastatic disease to the adrenal glands can occur in a wide array of
malignancies. With the increased use of abdominal imaging, these lesions
are diagnosed with more frequency. Diagnostic and laboratory evaluation
is essential for the differentiation of benign lesions from primary
malignant adrenal tumors or extra-adrenal metastasis. Computed
tomography (CT) and magnetic resonance imaging (MRI) characteristics,
as well as the adjunctive use of immunocytochemical techniques on
biopsy specimens, can allow accurate identification of metastatic lesions.
Surgical management of metastastic lesions is appropriate in selected
patients, primarily when representing the solitary site of metastatic
disease. The surgical approach, while debatable, can de done either
through open surgery or laparoscopically. Either approach appears
comparable in terms of oncologic efficacy in the carefully selected patient,
although laparoscopic adrenalectomy is associated with decreased pain

and improved convalescence. The surgeon’s skill in laparoscopic
technique, appropriate patient selection, and the ability to adhere to
oncologic principles, including complete excision without tumor spillage,
are of utmost importance when deciding the appropriate surgical
intervention.

The adrenal gland is a common site of metastasis and can be
afflicted by malignancies from a multitude of primary sites.1-3 The rich
sinusoidal blood flow and multiple pathways of arterial blood supply may
contribute to the high incidence of metastatic implantation.1,3 In one
autopsy review of 1,000 patients with malignancy, metastases to the
adrenal glands were found in 27% of patients.2 The most common sites
metastasizing to the adrenal glands are breast, lung, gastrointestinal
tract, skin (melanomas), and kidney. Lung and breast cancers have been
found to account for approximately 39% and 35% of adrenal metastases,
respectively, and adrenal metastases can be seen in up to 40% to 50% of
patients with melanomas and liver or renal cell cancers.2-4

Patients with adrenal metastasis are typically asymptomatic but can
uncommonly present with back pain, retroperitoneal hemorrhage, or
adrenal insufficiency.1,5 In one study, symptomatic metastases were
larger in size when compared to asymptomatic lesions and also were

associated with a significantly younger patient population.5
Overwhelmingly, however, the majority of adrenal metastases are either
discovered incidentally during the staging workup for a primary
malignancy or identified on repeat radiological studies for surveillance
after initial treatment. Over a 30-year period, Lam and Lo found that
adrenal metastases were most frequently discovered within a relatively
brief period of time after detection of the primary malignancy (median
latent period, 7 months), with less than 2% of cases having metastases
to the adrenals more than 5 years after diagnosis.5

Imaging

Improvements in imaging techniques have allowed the ready
detection and characterization of adrenal gland metastases.6-12 Computed
tomography (CT) with and without oral and intravenous iodinated contrast
is useful in assessing adrenal lesions. Oral contrast should be given to
distinguish the adrenal glands from surrounding organs. On CT,
metastatic lesions are generally nonspecific and can have a wide array of
radiographic features. The size can vary from less than a centimeter to a
large mass. They may have a discrete focus or be multifocal; they can be
smooth, irregular, or have a lobulated contour. Lesions can be unilateral
or bilateral, can show evidence of local invasion, and may be associated
with hemorrhage. Calcifications are a rare finding in metastatic lesions,
but necrosis may be present. Intracellular lipid content and vascular

enhancement are two CT criteria that can be useful in differentiating
benign adenomas from malignant adrenal masses.6 Metastatic lesions
typically have low levels of intracytoplasmic fat in the adrenal cortex as
compared to adenomas (70% of cases) and will have lower attenuation
than adenomas on noncontrast CT.6,7,10,11 After the administration of
iodinated contrast there is usually a more obvious heterogeneous
enhancement pattern compared to adenomas and a significantly delayed
contrast material washout.6,7,9

Magnetic resonance imaging (MRI) is another useful tool for
evaluating metastatic lesions to the adrenal glands. MRI can be used in
patients who have a contraindication to intravenous contrast, particularly
those with an iodine allergy or those in renal insufficiency. T1-weighted
magnetic resonance images of metastatic tumors have a signal intensity
that is similar to adrenal adenomas and may be confused with benign
lesions.6,7 On T2-weighted imaging, lesions are likely to be heterogeneous
and hyper-intense when compared to liver. T2-weighted imaging with
opposed-phase imaging (in and out of phase) will show no decrease in
intensity secondary to the decreased lipid content in the mass. After the
administration of intravenous gadoliniumcomplex, most tumors are
hyper-intense and show heterogeneous enhancement. Using T2-weighted
fat-suppressed images, MRI may distinguish between normal and
neoplastic tissue.7

Ultrasonography may detect adrenal lesions that are larger than 2
cm. However, ultrasound has not been as useful as CT in the evaluation
of metastatic adrenal lesions.13,14 The sensitivity and specificity for
ultrasound were found to be 79% and 61%, respectively, as compared to
84% and 98% for CT.13 Operator experience, body habitus, bowel gas,
and lack of specific imaging patterns are all impeding factors. Preliminary
results with positron emission tomography (PET) have shown some
promise in differentiating malignant lesions using 18-fluorodeoxyglucose,
but further studies are needed to better define the role of this technology
in assessing adrenal lesions.6

Clinical and Serological Diagnosis

Establishing a diagnosis of metastatic disease versus benign disease
is paramount. As discussed, metastatic lesions can have nonspecific
findings on imaging and thus can overlap with benign adrenal masses in
size and radiological detail. Patients should be questioned for signs and
symptoms of a metabolically active primary adrenal tumor, such as
hypertension, tachycardia, headache, palpitations, hirsutism, or change in
body habitus. A physical examination should be performed looking for the
stigmata of the other etiologies of adrenal pathology, including
examination for lymphadenopathy, thyroid lesions, and genitourinary
abnormalities. Serum electrolytes, as well as urine and serum analysis
for aldosterone, cortisol, sex hormone steroids, and catecholamines and

their metabolites such as metanephric acid, should be performed to
evaluate for primary adrenal tumors.15,16

Biopsy

Fine-needle aspiration (FNA) with CT guidance can be performed
safely and is highly sensitive and specific for diagnosing adrenal
metastasis.17,18 FNA also is useful for defining a primary malignancy of
unknown origin. The accuracy of FNA has improved with advances in
immunocytochemistry techniques, which have a specificity and sensitivity
reported to be as high as 85% to 94% and 100%, respectively.17 The best
diagnostic results are obtained when a cytopathologist and
cytotechnology assistant are present while specimens are obtained at the
time of FNA. Some cytologic indicators of metastatic lesions are increased
nuclear hyperchomasia, prominent nucleoli, necrotic debris, and intact
cells with increased nuclear/cytoplasmic ratios. The complication rate of
FNA have been reported to be approximately 3.0%, which may include
hemorrhage, infection, theoretical risk of tumor tract seeding, and
capsular disruption.17,19 There is also the risk of biopsy of an unrecognized
pheochromocytoma, which can cause life-threatening hemodynamic
instability. In a review by Fassancht et al, in patients with a
nonmetabolically active adrenal mass and inconclusive imaging, the
authors recommended an adrenal biopsy in the absence of other
metastasis.16

Surgical Management of Adrenal Metastasis

Surgical management of an adrenal lesion is indicated for the
removal of functional and nonfunctional tumors, including
pheochromocytoma, solid adrenal masses not meeting radiographic
criteria as benign lesions, and lesions greater than 5 cm.20 Open surgical
adrenalectomy can be performed by a variety of means, including
posterior and modified posterior, flank, and transabdominal approaches.
Laparoscopic adrenalectomy has emerged as the treatment of choice for
benign functioning and nonfunctioning adrenal disorders requiring
surgery. Most commonly, a transperitoneal approach is performed, but
retroperitoneal laparoscopy can be used.20 The choice of technique and
approach depends largely on the surgeon’s experience and preference,
size and location of the tumor, body habitus, previous intra-abdominal
surgery, or previous adhesions. Contraindictions to laparoscopy include
pregnancy, large tumors (_8 cm), or if primary invasive adrenocortical
carcinoma is suspected on imaging.

20,21

Other relative contraindications

include morbid obesity, prior intraabdominal surgery, and large
pheochromocytomas.

Several series confirm that surgical management of a metastatic
adrenal lesion does improve survival in select patients and can lead to
potential cure.19,22-32 In a series reported by Higashiyama et al, lung

cancer patients with isolated metastatic disease to the adrenal gland who
underwent surgical resection followed by adjuvant chemotherapy or
radiotherapy fared much better than patients treated non-operatively.27
This study demonstrated a median survival of less than 6 months for
patients treated medically, and survival benefit of greater than 9 months
in the surgical group, with one patient showing no disease progression
after 40 months. Luketich and Burt found a 3-year actuarial survival of
38% in solitary adrenal metastatic lesions from non-small cell lung cancer
managed with chemotherapy followed by adrenalectomy compared with
chemotherapy alone.26 The survival in the surgery group was significantly
improved with a median of 31 months, versus 8.5 months, and all of the
patients in the chemotherapy group without surgery died within 22
months.26

Several studies have tried to identify patients who may benefit from
surgical excision of metastatic adrenal lesions. Adrenalectomy has been
found to be most beneficial when the primary cancer is controllable and
when there is no evidence of extra-adrenal metastases.

30

Siemer et al

examined renal cell cancer patients and noted that patients with a solitary
adrenal metastasis achieved a significant tumor-specific survival benefit
with a median survival of 68 months compared to a median survival of 10
months in those patients with additional metastatic foci.25 Risk factors
such as the site of the primary cancer, size, histology, primary tumor type
(adenocarcinoma possibly being more favorable), presence of other

distant metastases, local invasion, and a lengthy disease-free interval
after initial diagnosis appear to impact on cancer survival, but these risk
factors have been somewhat variable.4,25-33

The optimal surgical approach for adrenalectomy for metastatic
lesions, either laparoscopic or open surgery, is somewhat controversial.
The majority of data regarding improved survival after adrenalectomy
have focused primarily on open surgical techniques. In a series from
Memorial Sloan-Kettering Cancer Center, Kim et al examined 37 patients
who underwent open adrenalectomy, and found a 5-year survival of 24%
(median survival, 21 months).29 They found that complete resection and a
disease-free interval of greater than 6 months were predictors of survival.
Advocates of open adrenalectomy voice many concerns with laparoscopy,
such as the possibility of tumor seeding and subsequent carcinomatosis
due to carbon dioxide insufflation, violation of the adrenal gland and
tumor spillage, the possible immunosuppressive affects of the
pneumoperitoneum, and potential port site metastasis as reasons to avoid
laparoscopic surgery.28,30,34,35 Additionally, Kebebew et al demonstrated
that inadvertent laparoscopic resection of clinically unsuspected
adrenocortical carcinoma exhibited a high local recurrence rate.19 Gerber
et al reported on their experience with laparoscopic adrenalectomy for
lung cancer patients with a solitary metastasis to the adrenal gland.36
They found that these patients had an inflammatory reaction that made
dissection during laparascopy more difficult than with benign disease to

the adrenal gland, and concluded that lesions greater than 5 cm are less
amenable to laparoscopic adrenalectomy and have a higher rate of open
conversion.

The incidence of port site metastasis has been estimated to be from
0% to 6.25%.35 Causes of port site metastasis can be grouped into
several categories: tumor aggressiveness (type of tumor and its natural
behavior), local wound factors (implanting in the early stages of wound
healing, tumor cell adherence to wound margins, and release of growth
factors), host immune response, and laparoscopy-related factors (ie, type
of gas used for insufflation, surgical manipulation, tumor spillage).35 In
their review of the urologic literature, Tsvian et al found nine cases of port
site metastasis. The putative causative factors of port site metastasis
were high stage or grade primary tumor, violation of tumor boundaries,
intracorporeal morcellation of the tumor specimen, and disuse of an
entrapment bag during specimen retrieval. Other potential risk factors
were pre-existing immunosuppression and the presence of ascites.35,37

There have been contradictory reports on the role of the
pneumoperitoneum as the cause of port site metastasis and
carcinomatosis.38-40 In an novel study by Ikramuddin et al, carbon dioxide
effluent recovered from patients with cancer during laparoscopy was
examined.

40

The authors concluded that malignant cells are aerosolized

in laparoscopic surgery, but in patients without carcinomatosis,
aerosolization is unlikely to contribute to port site metastasis.

Many proponents of laparoscopic surgery suggest that laparoscopic
adrenalectomy is oncologically comparable to open surgery for the
management of metastatic lesions to the adrenal in the selected patient.
In regards to port site seeding, proponents state that open adrenalectomy
is not exempt from wound recurrences. There is an approximately 0.4%
chance of metastasis in surgical scars after open surgery for renal cell
carcinoma.41 Laparoscopic adrenalectomy may have several advantages
over open surgical approaches. When compared to open surgery,
laparoscopy has demonstrated superior operative times, analgesic
requirements, postoperative complications, hospital stay, and mean
operative blood loss.42,43 Laparoscopic adrenalectomy appears to confer
the same survival benefit as open surgery.31,44 Sarela et al found no
difference in the median survival between open adrenalectomy and
laparoscopic adrenalectomy.45 In another series, 31 patients underwent
laparoscopic adrenalectomy for metastatic lesions from several primary
tumors, primarily colon, lung, and renal cell cancers.30 The 5-year
actuarial survival rate was 40% with a median follow-up of 26 months,
which was favorable when compared to historical open adrenalectomy
series. The authors emphasized that proper patient selection was critical,
and small organ-confined adrenal masses were best suited for a
laparoscopic procedure. Specific contraindications to laparoscopic

adrenalectomy were irregular adrenal masses with peri-adrenal infiltration
into adjacent organs. The authors suggested that a laparoscopic approach
should be abandoned if there are concerns regarding the adequacy of
wide excision, and care should be taken not to violate the adrenal mass,
to avoid tumor spillage, and to remove the specimen intact rather than
through morcellation, with the use of a laparoscopic bag to withdraw the
specimen.

Alternative approaches to the treatment of metastatic disease to the
adrenal gland have been examined.

43,44,46,47

Percutaneous radiofrequency

ablation (RFA) has exhibited some promise in treating malignant adrenal
tumors.43,44 RFA utilizes alternating radiofrequencies, which generate heat
and lead to tissue necrosis and destruction. In a preliminary study of RFA
of metastatic adrenal lesions, tumor recurrence occurred in two of 11
patients after RFA treatment.43 Percutaneous ethanol ablation is another
non-invasive approach that has been investigated for adrenal tumors.
Ethanol is cytotoxic and thrombogenic and has shown promise in shortterm studies.46,47 Although the specific roles for RFA and ethanol ablation
have not been established and long-term data are still pending, these
percutaneous techniques may have promise for patients who are nonoperative candidates or those who refuse surgical intervention.

Conclusion

The surgical management of adrenal metastatic lesions has shown
benefit in the survival of select patients with a variety of primary tumors.
Adrenal metastesectomy also has exhibited success when used as an
adjunct to chemotherapy, and has been found to be more successful than
chemotherapy and radiation alone. Controversy remains over the use of
laparoscopic adrenalectomy, although in a number of studies there seems
to be at least a parallel survival benefit when compared to open
adrenalectomy, with improved convalescence. The importance of patient
selection, surgeon comfort level and experience, adequate surgical
planning, and adherence to oncologic principles cannot be overstated
when performing laparoscopic adrenalectomy for metastastic lesions.
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